ADAG Adagene Inc. Stock Quote

ADAG [NASD]

Index	-	P/E	-	EPS (ttm)	-1.01	Insider Own	-	Shs Outstand	42.67M	Perf Week	6.59%
Market Cap	600.37M	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-	Shs Float	5.59M	Perf Month	-24.88%
Income	-42.60M	PEG	-	EPS next Q	-0.41	Inst Own	0.42%	Short Float	1.31%	Perf Quarter	-
Sales	0.70M	P/S	857.67	EPS this Y	-155.70%	Inst Trans	-	Short Ratio	0.39	Perf Half Y	-
Book/sh	-	P/B	-	EPS next Y	-34.80%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	1.76	P/C	7.98	EPS next 5Y	-	ROE	-	52W Range	12.67 - 31.83	Perf YTD	-53.08%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	53.10%	52W High	-56.02%	Beta	-
Dividend %	-	Quick Ratio	4.90	Sales past 5Y	-	Gross Margin	-	52W Low	10.50%	ATR	1.19
Employees	198	Current Ratio	4.90	Sales Q/Q	-18.50%	Oper. Margin	-	RSI (14)	33.30	Volatility	8.89% 8.05%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.00	Prev Close	14.07
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	187.60K	Price	14.00
Recom	1.70	SMA20	-10.18%	SMA50	-30.97%	SMA200	-31.61%	Volume	42	Change	-0.50%

Mar-08-21

Initiated

Morgan Stanley

Overweight

$34

Mar-08-21

Initiated

Jefferies

Buy

$33

Mar-08-21

Initiated

Goldman

Buy

$29

Apr-13-21 07:45AM	Adagene Presents Preclinical Data from Lead SAFEbody Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021 GlobeNewswire
Mar-31-21 07:45AM	Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates GlobeNewswire
Mar-29-21 07:45AM	Adagene Announces Clinical Advancement for ADG116 GlobeNewswire
Mar-16-21 08:05AM	Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody Program GlobeNewswire
Feb-11-21 10:08AM	Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option GlobeNewswire +12.98%
Feb-09-21 05:18PM	3 Chinese Companies Make Strong Market Debuts Barrons.com
09:00AM	Adagene Inc. Announces Pricing of Initial Public Offering GlobeNewswire

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience